Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Trevi Therapeutics, Inc. (TRVI : NSDQ)
 
 • Company Description   
Trevi Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. The company is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis and levodopa-induced dyskinesia in patients with Parkinson's disease. Trevi Therapeutics Inc. is based in New Haven, Connecticut.

Number of Employees: 24

 
 • Price / Volume Information   
Yesterday's Closing Price: $2.22 Daily Weekly Monthly
20 Day Moving Average: 193,212 shares
Shares Outstanding: 38.69 (millions)
Market Capitalization: $85.88 (millions)
Beta: 0.31
52 Week High: $3.73
52 Week Low: $0.46
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -33.13% -24.68%
12 Week 353.06% 398.11%
Year To Date 183.82% 246.78%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
195 CHURCH STREET 14TH FLOOR
-
NEW HAVEN,CT 06510
USA
ph: 203-304-2499
fax: -
chris.seiter@trevitherapeutics.com http://www.trevitherapeutics.com
 
 • General Corporate Information   
Officers
Jennifer Good - President and Chief Executive Officer; Director
David Meeker - Chairman
Lisa Delfini - Chief Financial Officer
Christopher Galletta - Controller
James V. Cassella - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 89532M101
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/11/22
Share - Related Items
Shares Outstanding: 38.69
Most Recent Split Date: (:1)
Beta: 0.31
Market Capitalization: $85.88 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.19 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.85 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/11/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 8.21
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 44.19%
vs. Previous Quarter: 14.29%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -232.28
12/31/21 - -194.29
09/30/21 - -174.53
ROA
03/31/22 - -94.26
12/31/21 - -89.27
09/30/21 - -86.96
Current Ratio
03/31/22 - 2.32
12/31/21 - 2.98
09/30/21 - 3.10
Quick Ratio
03/31/22 - 2.32
12/31/21 - 2.98
09/30/21 - 3.10
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 0.27
12/31/21 - 0.66
09/30/21 - 0.47
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.67
12/31/21 - 0.51
09/30/21 - 0.90
Debt-to-Capital
03/31/22 - 40.28
12/31/21 - 33.63
09/30/21 - 47.38
 

Powered by Zacks Investment Research ©